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Abstract
Background: Tuberculosis (TB) control relies on early diagnosis and treatment. International guidelines recommend
systematic TB screening at health facilities, but implementation is challenging. We investigated completion of
recommended TB screening steps in Blantyre, Malawi.
Methods: A prospective cohort recruited adult outpatients attending Bangwe primary clinic. Entry interviews were
linked to exit interviews. The proportion of participants progressing through each step of the diagnostic pathway
were estimated. Factors associated with request for sputum were investigated using multivariable logistic
regression.
Results: Of 5442 clinic attendances 2397 (44%) had exit interviews. In clinically indicated participants (n = 445) 256
(57.5%) were asked about cough, 36 (8.1%) were asked for sputum, 21 (4.7%) gave sputum and 1 (0.2%) received
same-day results. Significant associations with request for sputum were: any TB symptom (aOR:3.20, 95%CI:2.02–
5.06), increasing age (aOR:1.02, 95%CI:1.01–1.04 per year) and for HIV-negative participants only, a history of
previous TB (aOR:3.37, 95%CI:1.45–7.81). Numbers requiring sputum tests (26/day) outnumbered diagnostic capacity
(8–12/day).
Conclusions: Patients were lost at every stage of the TB care cascade, with same day sputum submission following
all steps of the diagnosis cascade achieved in only 4.7% if clinically indicated. Infection control strategies should be
implemented, with reporting on early steps of the TB care cascade formalised. High-throughput screening
interventions, such as digital CXR, that can achieve same-day TB diagnosis are urgently needed to meet WHO End
TB goals.
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Background
Tuberculosis (TB) is the leading infectious cause of
death worldwide and an estimated 10 million people de-
veloped TB disease in 2019 [1, 2]. TB control relies on
early diagnosis and treatment, as reflected in the World
Health Organization (WHO) End TB 2025 target of
≥90% of people who develop TB being notified and
treated [3]. To achieve this the WHO recommends sys-
tematic TB screening for priority risk groups in order to
reduce poor disease outcomes and TB transmission [4].
These recommendations are reflected in many National
TB Programme (NTP) guidelines [5–8].
The TB care cascade model assesses patient progres-
sion and retention through sequential stages of care re-
quired to achieve a successful treatment outcome [9], in
order to quantify gaps in care delivery and adherence to
guidelines. Care cascades have been extensively used to
evaluate HIV care delivery [10], but have only recently
been applied by TB programmes [9] to expand analysis
beyond standardised treatment outcome reporting [11]
and ad hoc diagnostic pathway analysis [12].
In Subbaraman et al’s generic model for a care cascade
for active TB the first gap is identified as not accessing a
TB diagnostic test [9]. This first gap is repeatedly the
largest in many settings [13, 14], in keeping with the nu-
merous issues relating to sputum-based tests [15].
Recent studies have emphasised variability in TB diag-
nosis cascades in high burden countries. In India, only
12–17% of standardised patients were correctly asked to
test for TB [16], whereas in Nairobi, Kenya [17] this was
50% and a systematic review found a range for all pa-
tients from 4% in Thailand to 84% in South Africa [18].
However, most high-burden TB countries, do not rou-
tinely collect data to estimate adherence to systematic
TB screening guidelines in health facilities.
WHO recommends people living with HIV are sys-
tematically screened for TB each time they visit a health
facility and that in high-burden TB settings systematic
screening for TB in other selected high risk groups may
also be appropriate [4]. These risk groups include older
people and those previously treated for TB. However, an
estimated 29% of new TB cases are still not identified or
officially notified, partly due to failure to diagnose active
TB in people accessing healthcare [1, 19]. Examining TB
test access for these risk groups and subsequent steps in
the TB diagnosis cascade will be critical for efficient TB
programme design.
The aims of this study were to: construct a TB
diagnosis care cascade; describe the proportion of
“clinically-indicated” patients (defined by the Malawi
National guidelines [5]) who progressed through each
step of the diagnosis cascade in a primary care clinic;




A prospective cohort of adults aged 18 years and older
was recruited from May to September 2018. The study
formed part of the pilot phase of a randomised trial at
Bangwe health clinic in Blantyre, Malawi [20].
Study site and population
Patients self-presenting to free-of-charge acute-care ser-
vices in Bangwe Health Centre – a government primary
care clinic – were recruited prospectively. There are no
physicians at the clinic; care is provided by nurses and
clinical officers, who conduct consultations, including
TB symptom screening, with the patients. There is a
GeneXpert machine for TB sputum diagnosis and TB
treatment is available on site. TB prevalence in Blantyre
was 1% in 2013 [21] and 113 new registrations for TB
treatment were recorded at Bangwe health centre during
2018 (unpublished data).
Malawi National TB Programme guidelines state that
all adults with HIV presenting to healthcare facilities
with any TB symptom (any of cough, night sweats, fever
or weight loss) should receive a sputum test for TB [5].
For HIV-negative adults sputum tests are recommended
for all those with weight loss or other TB symptoms of
two weeks or more. For the purposes of this study ‘clin-
ically indicated to submit sputum’ was defined as adults
with HIV with any TB symptom and HIV-negative
adults with weight loss or a chronic cough (two weeks
or more), since duration data was not collected for night
sweats or fever. A sensitivity analysis was conducted
with an alternative definition including any symptom of
any duration for people without HIV infection.
Data collection
Research assistants stationed at the registration desk in
the acute-care clinic asked all patients for verbal consent
to participate. A fingerprint scan with demographic de-
tails was recorded electronically at entry interview. Add-
itional research assistants positioned by the two clinic
exits asked all adults leaving the clinic to participate in
exit interviews. Participants provided written or wit-
nessed fingerprint (if illiterate) consent for exit
interviews.
Entry and exit interviews were linked through digital
fingerprint bio-identification. Entry interviews recorded
age, sex and WHO recommended TB symptom screen-
ing [4, 22]. Exit interviews asked about care received at
the clinic and included self-reported HIV status and pre-
vious TB diagnosis; whether a health worker had
enquired about cough; if they had been asked to submit
sputum; if they submitted sputum; and if sputum results
had been received. For simplicity, the exit interview en-
quiry about symptom screening referred only to cough,
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as this is the most commonly recognised TB symptom
in Malawi [23]. Questionnaires were kept brief to min-
imise inconvenience and maximise the completeness of
capture (see Suppl Table 2 for full questionnaires).
Statistical methods
Summary statistics compared characteristics (collected
at clinic entry) of participants who had exit interviews
with those who had not (χ2 and Kruskal-Wallis tests).
Participant characteristics were also compared by HIV
status (HIV-positive, HIV-negative, status unknown/
never tested). “Chronic cough” was defined as cough ≥2
weeks. “Any TB symptom” included any reported cough,
fever, weight loss or night sweats [24].
Diagnosis care cascades were constructed based on all
participants, and separately for clinically-indicated
groups: HIV-negative participants with weight loss or
chronic cough and people living with HIV (PLHIV) with
any TB symptom. Generic care cascade Step 2 ‘Accessed
TB tests’ [9] was expanded to explore symptom enquiry
(cough); request to submit sputum; and sputum
submission.
Univariable and multivariable logistic regression were
used to investigate associations of clinical and demo-
graphic characteristics with request for sputum submis-
sion. Separate models were fit for ‘any TB symptom’ and
specific individual TB symptoms. Sex, age and symptom
variables included in the Malawi Tuberculosis Guideline
[5] were included a priori in the multivariable models.
Those who reported a cough and being on TB treat-
ment or isoniazid preventive therapy (IPT) at clinic entry
were removed from the cascade and multivariable
analysis.
Ethical considerations
Approval was received from the research ethics commit-
tees of the College of Medicine, Malawi and Liverpool
School of Tropical Medicine. All participants provided
written informed consent (or witnessed, thumb-print
consent if illiterate).
Data and reproducibility




Of 5442 clinic attendances 2397 (44%) had matched exit
interviews, mainly reflecting limited study capacity to
interview everyone leaving the clinic (Fig. 1). Five indi-
viduals declined to participate in entry interviews and
were not included in the study. None refused to partici-
pate in exit interviews.
Participants with matched exit interviews had similar
characteristics to those with just an entry interview, with
some differences: men were more likely to complete an
exit interview (37.5% vs 34.2%, p = 0.012) as were those
with any TB symptom (57.2% vs 54.4%, p = 0.044). This
was consistent for cough, fever and night sweats. Those
completing exit interviews were older than those who
did not (median age 28 vs 27 years) (Suppl Table 1).
Exit interviewee characteristics
Of the 2397 with matched exit interviews 900 (37.5%)
were male. Median age was 28 years (range 18–89). A
total of 849 (35.4%) had a cough, with 221 (9.2%) having
chronic cough, and 1370 (57.2%) having any TB symp-
tom. Previous TB treatment was reported by 141 (5.9%).
Among HIV positive participants (292, 12.2%) almost all
were taking antiretroviral therapy (ART) (276, 94.5%).
Of those completing exit interviews 1485 (62.0%) self-
reported good health.
HIV positive participants were more likely than HIV-
negative or status-unknown participants to be female
(72.9% vs 62.7 and 50.7%, p < 0.001) and older (median
age 36 years vs 27 years and 27.5 years for HIV-positive,
HIV-negative and HIV-unknown respectively, p < 0.001)
(Table 1). PLHIV were also more likely to be taking TB
treatment (14.9% vs 3.2 and 1.8%), on IPT (21.5% vs 1.1
and 1.8%) and to report previous TB (22.6% vs 3.6 and
3.0% for HIV-positive, HIV-negative and HIV-unknown
respectively) (all p < 0.001). A higher proportion of
PLHIV had chronic cough (15.1%) compared to HIV-
negative (8.2%) or unknown-status participants (9.5%,
p = 0.001).
75 participants who reported being on TB treatment
(40 people) or isoniazid preventive therapy (IPT) (35
people) were not included in the cascade or multivari-
able analysis.
TB diagnosis cascades
Of all 2322 exit interview participants analysed 1322
(56.9%) were asked by health workers about cough, 118
(5.1%) were asked to submit sputum, 46 (2.0%) gave
same-day sputum and 3 (0.1%) received same-day
results.
445 participants were clinically-indicated to submit
sputum (HIV-negative participants with weight loss or
chronic cough, and PLHIV with any TB symptom). 256
(57.5%) of these reported having been directly asked
about coughing, with 36 of those (36/445, 8.1% of total)
asked to submit a sputum sample; 21/445 (4.7%) pro-
vided same-day sputum and 1/445 (0.2%) received same-
day sputum results (Fig. 1).
Diagnosis care cascades were constructed separately
for each clinically-indicated group: HIV-negative partici-
pants with weight loss or chronic cough and PLHIV with
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Fig. 1 Consort diagram of cohort participants and progress through steps of the TB diagnosis cascade
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any TB symptom (Fig. 2). In the 308 HIV-negative partici-
pants with chronic cough, 57.8% were asked about cough,
6.5% were also asked for sputum, 3.6% gave sputum and
none received same-day results. Among the 137 PLHIV with
any TB symptom 56.9% were asked about cough, 11.7% were
also asked for sputum, 7.3% gave sputum and 0.7% received
same-day results. Overall sputum submission for TB testing
was achieved in 5.4% (24/445) of clinically-indicated partici-
pants with 4.7% (21/445) successfully progressing through all
steps of the diagnosis cascade to this point (four clinically in-
dicated participants were requested to give sputum but had
not been asked about cough).
Of the 118 requested to submit sputum 78 (66.1%)
were not classed as clinically indicated. Of these 10/78
(12.8%) had unknown HIV status and TB symptoms, 27/
78 (34.6%) were HIV-negative with no chronic cough or
weight loss but had night sweats or fever of unknown
duration and 17/78 (21.8%) were HIV-negative with
cough of < 2 weeks as their only TB symptom. 24/78
(30.8%) participants (of whom 2 were HIV-positive)
reported being asked to submit sputum but did not re-
port any TB symptoms.
Using a more sensitive definition for clinically indicated par-
ticipants (HIV-positive with any TB symptom and HIV-
negative with chronic cough or weight loss, night sweats or
fever of any duration) reduced the proportion of clinically in-
dicated participants asked to submit sputum to 5.7% (8.1% in
original definition) and those who submitted sputum to 2.4%
(4.7% originally).
For all clinically-indicated groups, the biggest gap in
the diagnosis cascade was between symptom enquiry
and requesting sputum with 49.4% (220 of 445 who were
clinically indicated for sputum testing) lost at this stage
compared to 42.5% (189/445) not asked about cough
and 3.4% (15/445) not giving sputum despite health
worker request. For HIV-negative participants with
weight loss or chronic cough, clinicians requested spu-
tum for 11.2% (20/178) of those they had asked about
cough and in PLHIV with any TB symptom this was
20.5% (16/78).
Table 1 Baseline characteristics of exit interview participants by HIV status
HIV+ (N = 292) HIV- (N = 1809) Don’t know/never tested (N = 296) P value
Sex (Female) 213 (72.9%) 1134 (62.7%) 150 (50.7%) < 0.001
Age Median (Range) 36 (18–70) 27 (18–87) 27 (18–89) < 0.001
Age 18–29 89 (30.5%) 1031 (57.0%) 159 (53.7%) < 0.001
30–39 98 (33.6%) 391 (21.6%) 46 (15.5%)
40–49 68 (23.3%) 190 (10.5%) 25 (8.4%)
50–59 22 (7.5%) 95 (5.3%) 27 (9.1%)
60–89 15 (5.1%) 102 (5.6%) 39 (13.2%)
Cough 121 (41.4%) 618 (34.2%) 110 (37.2%) 0.044
Cough days (if cough) Median (Range) 7 (1–3650) 4 (1–2190) 4 (2–1095) 0.001
Chronic cough¶ 44 (15.1%) 149 (8.2%) 28 (9.5%) 0.001
Weight loss 65 (22.3%) 223 (12.3%) 28 (9.5%) < 0.001
Fever 92 (31.5%) 550 (30.4%) 92 (31.1%) 0.915
Night sweats 56 (19.2%) 342 (18.9%) 63 (21.3%) 0.629
Any symptoms† 181 (62.0%) 1007 (55.7%) 182 (61.5%) 0.035
Previous TB 66 (22.6%) 66 (3.6%) 9 (3.0%) < 0.001
On TB treatment* 18 (14.9%) 20 (3.2%) 2 (1.8%) < 0.001
TB treatment last 6 months* 2 (1.7%) 7 (1.1%) 0 (0.0%) 0.446
On IPT* 26 (21.5%) 7 (1.1%) 2 (1.8%) < 0.001
ART 276 (94.5%) 0 (0%) 0 (0%) < 0.001
Self-reported general health
Very Good 5 (1.7%) 58 (3.2%) 13 (4.4%) 0.062
Good 159 (54.5%) 1091 (60.3%) 159 (53.7%)
Fair 122 (41.8%) 622 (34.4%) 119 (40.2%)
Poor/Very poor 6 (2.1%) 38 (2.1%) 5 (1.7%)
† Any TB symptom: cough, or weight loss, or fever, or weight loss
¶ Cough of 14 days or longer
* Only recorded if patient had cough
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Factors associated with being asked to submit sputum
On univariable analysis for all participants (Table 2),
factors significantly associated with being asked to
submit sputum included: older age (OR: 1.02, 95%CI:
1.01–1.03 per year increase in age), previous TB treat-
ment (OR: 2.13, 95%CI: 1.08–4.20); being HIV-
positive (OR: 1.69, 95%CI: 1.02–2.80); and presence of
any TB symptoms (cough< 2 weeks OR: 2.48 (95%CI:
1.70–3.61), chronic cough OR: 3.32 (95%CI:2.07–
5.33), weight loss OR: 2.52 (95% CI: 1.63–3.89), fever
OR 2.10 (95% CI: 1.44–3.06) and night sweats OR
1.86 (95%CI: 1.23–2.80)).
Fig. 2 Diagnosis care cascades for groups clinically indicated for TB sputum tests
Table 2 Univariable and multivariable associations with being asked to submit sputum: all participants. n = 2322




OR (95% CI) P value aOR (95% CI) P value aOR (95% CI) P value
Sex 1.02 (0.69–1.49) 0.936 1.01 (0.68–1.49) 0.975 1.08 (0.73–1.62) 0.695
Age 1.02 (1.01–1.03) < 0.001 1.02 (1.01–1.04) < 0.001 1.02 (1.01–1.03) 0.002
Previous TB 2.13 (1.08–4.20) 0.026 1.64 (0.79–3.37) 0.183 1.59 (0.75–3.37) 0.224
HIV + * 1.69 (1.02–2.80) 0.040 1.42 (0.84–2.42) 0.191 1.45 (0.85–2.49) 0.174
Any TB symptom† 3.27 (2.07–5.18) < 0.001 3.20 (2.02–5.06) < 0.001 – –
Cough < 2 weeks 2.48 (1.70–3.61) < 0.001 – – 3.43 (2.23–5.28) < 0.001
Chronic cough 3.32 (2.07–5.33) < 0.001 – – 3.71 (2.10–6.56) < 0.001
Weight loss 2.52 (1.63–3.89) < 0.001 – – 1.54 (0.96–2.47) 0.076
Fever 2.10 (1.44–3.06) < 0.001 – – 1.43 (0.94–2.18) 0.096
Night sweats 1.86 (1.23–2.80) 0.003 – – 1.05 (0.66–1.68) 0.827
* Reference group: HIV-negative. Status unknown not presented
† Any TB symptom: cough, or weight loss, or fever, or weight loss
¶ Cough of 14 days or longer
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On multivariable analysis increasing age (adjusted OR:
1.02, 95%CI: 1.01–1.04 per year) and any TB symptom
(adjusted OR: 3.20, 95%CI: 2.02–5.06) remained signifi-
cantly associated with being asked to submit sputum for
all participants. In the individual symptoms multivariable
model presence of cough (both under and over 2 weeks
duration) was the only symptom still significantly associ-
ated with request for sputum (cough< 2 weeks adjusted
OR 3.43, 95%CI: 2.23–5.28, chronic (≥2 weeks) cough
adjusted OR: 3.71, 95%CI: 2.10–6.56) (Table 2).
On stratification by HIV status all these factors
remained significantly associated for HIV-negative par-
ticipants, but only the presence of any TB symptom
(OR: 8.24, 95%CI: 1.08–37.68, adjusted OR: 8.18, 95%CI:
1.85–36.21) and chronic cough (OR: 10.84, 95%CI: 3.66–
32.09, adjusted OR: 13.06, 95%CI: 3.69–46.28) were sig-
nificantly associated with request for sputum amongst
PLHIV (Table 3).
Sputum test throughput and capacity
If all patients clinically indicated for a TB test did submit
sputum (445/44% [percentage completing exit inter-
view] = 1011 over the 78 working days of the study) that
would result in ~ 26 sputum samples on each working
day (13 patients a day, each with two samples). The
clinic laboratory has one GeneXpert machine to process
TB samples, with a maximum throughput of 8–12 sam-
ples a day (4 samples per cartridge with 2 h run time
plus preparation).
Discussion
This study found that same day sputum submission for
TB testing following all steps of the diagnosis cascade
was achieved for only 4.7% of participants among whom
sputum testing was indicated according to Malawi na-
tional guidelines, with patients lost at every stage of the
TB diagnosis care cascade. Failure to request sputum by
clinicians despite elicited symptoms led to the biggest
single gap in the diagnosis care cascade, followed by not
asking about symptoms. This suggests that: interventions
focusing on health worker behaviour may have the
greatest potential for retaining presumptive TB patients
within the diagnosis cascade; there appears to be incon-
sistent application of guidelines and infection control
practices; and that we must formalise and strengthen
reporting on the early steps in the TB care cascade. Add-
itional important epidemiological groups such as men
[1] should be given equal priority to PLHIV within na-
tional TB guidelines. However, if guideline adherence is
improved, novel high-throughput triage testing ap-
proaches will also be needed to reach the required
capacity.
Adherence to sputum-request guidelines in 4.7% (21/
445) of patients sits at the bottom of the range (4–84%)
identified in a recent systematic review [18]. When taken
together with a TB treatment initiation rate of 85–94%
[25] and TB treatment success rate of 82% in Malawi
[19], our data suggests that the overall TB cascade in
Malawi is more similar to that for India than that for
South Africa. In India gap 1 (did not access a TB diag-
nostic test) accounted for 50% of all patient losses,
whereas in South Africa, low treatment success led to
the largest gap in the cascade [9, 13, 16].
To reduce these substantial gaps in accessing TB tests
a multi-faceted approach is required to identify logistical
barriers and change health worker behaviours. Facility-
based screening relies on health worker behaviour (ask-
ing about symptoms and requesting sputum) which
leads to the biggest gaps and therefore offers the greatest
potential for improvement. Suspicion of malaria or bac-
terial investigations may contribute to not requesting
sputum [26] but further investigation is needed to con-
firm what structural factors drive health worker
behaviour.
This study demonstrates a low level of adherence to
National TB Programme guidelines. This is the case





Univariable Multivariable Univariable Multivariable
OR (95% CI) P value aOR (95% CI) P value OR (95% CI) P value aOR (95% CI) P value
Sex 1.15 (0.40–3.29) 0.801 1.08 (0.35–3.32) 0.891 1.04 (0.67–1.62) 0.867 1.18 (0.74–1.87) 0.485
Age 1.02 (0.98–1.06) 0.394 1.02 (0.98–1.06) 0.383 1.02 (1.01–1.04) 0.001 1.02 (1.01–1.04) 0.008
Previous TB 0.51 (0.11–2.28) 0.367 0.52 (0.11–2.48) 0.413 3.66 (1.67–8.06) 0.001 3.37 (1.45–7.81) 0.005
Any TB symptom† 8.24 (1.80–37.68) 0.001 8.18 (1.85–36.21) 0.006 2.56 (1.56–4.20) < 0.001 -* -*
Cough < 2 weeks 1.28 (0.44–3.72) 0.645 -* -* 2.59 (1.68–4.01) < 0.001 3.16 (1.94–5.13) < 0.001
Chronic cough¶ 10.84 (3.66–32.09) < 0.001 -* -* 2.37 (1.30–4.33) 0.004 2.56 (1.25–5.25) 0.010
† Any TB symptom: cough, or weight loss, or fever, or weight loss
¶ Cough of 14 days or longer
* Multivariable analysis for HIV+ presented for Any TB symptom model, for HIV- presented model includes individual symptoms. Other symptoms (weight loss,
fever and night sweats included in model but not presented: no significant relationship on multivariate analysis)
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even with groups identified as high risk within both the
Malawi and WHO guidelines, such as those who have
previously had TB and PLHIV. Health workers operate
in challenging conditions with average patient consult-
ation times < 3 min [27], a high turnover of staff and
regular supply stock outs [28]. As such, measures under-
taken to improve adherence to guidelines and increase
the proportion of clinically-indicated patients who access
TB tests need to be pragmatic. Strategies such as FAST -
Finding TB cases Actively, Separating safely and Treat-
ing effectively – [29] are effective in increasing testing
and infection control not only for TB but also other re-
spiratory infections. In Malawi, some elements of FAST,
such as cough monitors, have been inconsistently imple-
mented, due to limited availability of resources. How-
ever, our analysis shows the large gap in cough and
symptom enquiry that could be met by universal cough
monitors. Implementing strategies such as FAST con-
sistently is critical for all low and middle income coun-
tries (LMICs), especially in the midst of the COVID-19
pandemic.
In addition, enhanced monitoring and central collation
of data are essential to tracking individual clinic per-
formance. Malawi, as is typical for LMICs, collects and
reports comprehensive data on TB case notification and
treatment success at clinic level, but only reports the
number of TB tests per facility per quarter, without fur-
ther diagnostic steps. A WHO recommendation to re-
port numbers of screened presumptive TB cases,
disaggregated by age, gender and HIV-status globally,
would allow greater focus on the earlier steps of the TB
care cascade.
Despite TB prevalence in men being over twice as high
as among women in LMICs [30] and in Malawi a ratio
of male to female cases of 1.5 [1, 19], in our study sex
was not associated with being requested to submit spu-
tum. In Malawi, the ratio of prevalent-to-notified cases
of TB – an indication of how long patients take to be di-
agnosed - is 1.5 times higher among men than women
[30]. Men should, therefore, be considered as much of a
priority group within TB guidelines as PLHIV in coun-
tries with a high male-to-female case ratio. Notably, men
are less likely than women to seek health care early on
in their illness [31], making it critical to manage them
efficiently when they do present to a facility.
Finally, if all patients attending the outpatient clinic
were screened for TB as per the guidelines, the current
Xpert facilities would only be able to process up to a half
of the required samples. It is unknown to what extent
this lack of diagnostic capacity may influence test deci-
sions among the health workers. If guideline adherence
and increased identification of presumptive TB patients
is subsequently improved a novel high-throughput ap-
proach to triage testing using new diagnostics (e.g.
computer aided diagnostics for X-rays) will also be re-
quired for LMICs to increase capacity [32, 33].
Study limitations include the single site nature of this
study, limiting generalisability, although the study site is
typical of urban primary care clinics in Malawi so likely
representative of primary care in the areas with highest
TB burden in the country [21]. Due to limited research
staff capacity we interviewed only 44% of clinic attendees
with men and those with TB symptoms more likely to
complete an exit interview (Suppl Table 1), potentially
resulting in selection bias and overestimation of the pro-
portion who are clinically-indicated. However, this is
mitigated by high participation in those approached.
Symptoms, HIV status and testing practices were self-
reported, potentially resulting in social desirability bias
in measurement of these variables, with HIV-positive
status under-reported by up to 40% in Malawi [34] and
extensive dual HIV and TB stigma [35]. Although
healthcare workers would be dependent on the same
self-report of TB symptoms to assess eligibility for spu-
tum testing and the proportions progressing through
each step of the diagnosis cascade were similar for all
HIV status groups. In addition, 69.5% of patients asked
to submit sputum were not clinically-indicated to do so
as per our definition and 30.8% of those had no reported
TB symptoms at all – it is unknown why sputum was re-
quested from these patients.
Conclusion
Same-day sputum submission for TB testing following
all steps of the diagnosis cascade was achieved in only
4.7% of those clinically indicated. Requesting sputum
after eliciting symptoms is the key point of the cascade
to intervene. Interventions are needed to optimise TB
screening guidelines, formalise reporting, increase guide-
line adherence and improve diagnostic capacity, in order
to reduce the most significant gaps early in the TB care
cascade and to reach the required testing capacity to
meet the WHO End TB goals.
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